These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30063124)

  • 1. Regulation of TRPV5 transcription and expression by E2/ERα signalling contributes to inhibition of osteoclastogenesis.
    Song T; Lin T; Ma J; Guo L; Zhang L; Zhou X; Ye T
    J Cell Mol Med; 2018 Oct; 22(10):4738-4750. PubMed ID: 30063124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen inhibits RANKL-induced osteoclastic differentiation by increasing the expression of TRPV5 channel.
    Chen F; Ouyang Y; Ye T; Ni B; Chen A
    J Cell Biochem; 2014 Apr; 115(4):651-8. PubMed ID: 24150765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone resorption.
    van der Eerden BC; Hoenderop JG; de Vries TJ; Schoenmaker T; Buurman CJ; Uitterlinden AG; Pols HA; Bindels RJ; van Leeuwen JP
    Proc Natl Acad Sci U S A; 2005 Nov; 102(48):17507-12. PubMed ID: 16291808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
    Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
    Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast.
    Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W
    Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice.
    Choi JH; Jang AR; Kim DI; Park MJ; Lim SK; Kim MS; Park JH
    Exp Mol Med; 2018 Aug; 50(8):1-15. PubMed ID: 30154485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
    Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
    J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α.
    Wang L; Qiu XM; Gui YY; Xu YP; Gober HJ; Li DJ
    Drug Des Devel Ther; 2015; 9():3755-66. PubMed ID: 26229438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLIT2 inhibits osteoclastogenesis and bone resorption by suppression of Cdc42 activity.
    Park SJ; Lee JY; Lee SH; Koh JM; Kim BJ
    Biochem Biophys Res Commun; 2019 Jun; 514(3):868-874. PubMed ID: 31084928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The calcium channel TRPV6 is a novel regulator of RANKL-induced osteoclastic differentiation and bone absorption activity through the IGF-PI3K-AKT pathway.
    Ma J; Zhu L; Zhou Z; Song T; Yang L; Yan X; Chen A; Ye TW
    Cell Prolif; 2021 Jan; 54(1):e12955. PubMed ID: 33159483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPSTI1 promotes osteoclast differentiation and bone resorption by PKR/NF-κB signaling.
    Zhang M; Yang E; Qin X; Zhang S; Zhu Y; Fu H; He B
    Biochem Biophys Res Commun; 2024 Nov; 734():150463. PubMed ID: 39083969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-related receptor γ negatively regulates osteoclastogenesis and protects against inflammatory bone loss.
    Kim HJ; Kim BK; Ohk B; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR
    J Cell Physiol; 2019 Feb; 234(2):1659-1670. PubMed ID: 30076703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
    Hu B; Sun X; Yang Y; Ying Z; Meng J; Zhou C; Jiang G; Li S; Wu F; Zhao X; Zhu H; Wu H; Cai X; Shi Z; Yan S
    FASEB J; 2019 Feb; 33(2):2574-2586. PubMed ID: 30285579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARγ and APC.
    Guo L; Chen K; Yuan J; Huang P; Xu X; Li C; Qian N; Qi J; Shao Z; Deng L; He C; Xu J
    J Cell Physiol; 2018 Jan; 234(1):581-594. PubMed ID: 30272823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
    Song J; Jing Z; Hu W; Yu J; Cui X
    Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
    Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
    Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oleanolic acid inhibits RANKL-induced osteoclastogenesis via ER alpha/miR-503/RANK signaling pathway in RAW264.7 cells.
    Xie BP; Shi LY; Li JP; Zeng Y; Liu W; Tang SY; Jia LJ; Zhang J; Gan GX
    Biomed Pharmacother; 2019 Sep; 117():109045. PubMed ID: 31176167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.